A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

Author： Lin Nancy   Freedman Rachel   Ramakrishna Naren   Younger Jerry   Storniolo Anna   Bellon Jennifer   Come Steven   Gelman Rebecca   Harris Gordon   Henderson Mark   MacDonald Shannon   Mahadevan Anand   Eisenberg Emily   Ligibel Jennifer   Mayer Erica   Moy Beverly   Eichler April   Winer Eric  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.142, Iss.2, 2013-11, pp. : 405-414

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

By Iwata Hiroji   Narabayashi Masaru   Ito Yoshinori   Saji Shigehira   Fujiwara Yasuhiro   Usami Shigeyuki   Katsura Koichi   Sasaki Yasutsuna  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 621-628

Springer Publishing Company

Access to resources Recommend Favorite

Occult brain metastases in HER2-positive breast cancer patients: Frequency and response to radiotherapy

By Niwinska Anna   Tacikowska Małgorzata   Pienkowski Tadeusz  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 1027-1029

Informa Healthcare

Access to resources Recommend Favorite

Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea

By Jang Geundoo   Lee Sung   Ahn Jin-Hee   Jung Kyung   Lee Hyunjoo   Gong Gyungyub   Kim Hak-Hee   Ahn Seung   Son Byung   Ahn Sei-Hyun   Kim Sung-Bae  

Breast Cancer Research and Treatment, Vol. 128, Iss. 1, 2011-07 ,pp. : 171-177

Springer Publishing Company

Access to resources Recommend Favorite

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

By Alvarez Ricardo  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 103-110

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1351-1358

Spandidos Publications

Access to resources Recommend Favorite